IRVINE, CA--(Marketwire - Aug 23, 2012) - Itonis, Inc. (PINKSHEETS: ITNS) today announced the completion of financial audits for the most recently ended fiscal years. De Joya Griffith, Certified Public Accounts and Consultants, recently rendered an audit letter to the Company expressing opinions regarding the balance sheets of Itonis, Inc. as of November 30, 2011 and November 30, 2010 and the related consolidated statements of operations, stockholders' deficit and cash flows for the years ended from December 1, 2009 through November 30, 2011.
Mark Cheung, CEO of Itonis, Inc., commented, "The completion of this audit is an important step in providing the level of transparency our investors deserve. This furthers our goal of providing all available information in a timely manner. We believe we are putting together a strong operation that will realize the growth we, and our investors, expect. We all are especially excited about the introduction of the recently created Itonis Pharmaceuticals division headed by Zicam® Cold Remedy inventor and pharmaceutical industry pioneer, Dr. Charles Hensley. We look forward to working with Dr. Hensley as he rolls out his first over-the-counter formulation over the coming months and as our product categories continue to take shape."
About Itonis, Inc.
Itonis, Inc. trades under the symbol ITNS, and is a holding company with a variety of assets specifically selected to produce potentially high-growth revenue streams and meaningful returns for investors. For more information, please visit www.itonisholdings.com.
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is led by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives, and are based on commonly available and generally accepted as safe ingredients. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.